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Abstract
Orofacial clefting is amongst the most common of birth defects, with both genetic and envi-
ronmental components. Although numerous studies have been undertaken to investigate
the complexities of the genetic etiology of this heterogeneous condition, this factor remains
incompletely understood. Here, we describe mutations in the HYAL2 gene as a cause of
syndromic orofacial clefting. HYAL2, encoding hyaluronidase 2, degrades extracellular hya-
luronan, a critical component of the developing heart and palatal shelf matrix. Transfection
assays demonstrated that the gene mutations destabilize the molecule, dramatically reduc-
ing HYAL2 protein levels. Consistent with the clinical presentation in affected individuals,
investigations of Hyal2-/- mice revealed craniofacial abnormalities, including submucosal
cleft palate. In addition, cor triatriatum sinister and hearing loss, identified in a proportion
of Hyal2-/- mice, were also found as incompletely penetrant features in affected humans.
Taken together our findings identify a new genetic cause of orofacial clefting in humans and
mice, and define the first molecular cause of human cor triatriatum sinister, illustrating the
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fundamental importance of HYAL2 and hyaluronan turnover for normal human and mouse
development.
Author Summary
Cleft lip and palate (CLP) is one of the most common congenital anomalies worldwide.
Most of the time the cause is unknown. Affected individuals have multiple problems
including difficulties with feeding and speech and have to undergo several operations to
correct the orofacial cleft. We describe mutations in an enzyme involved in the develop-
ment of the palate and heart (Hyaluronidase 2, HYAL2) as the cause of a syndrome of
CLP and a congenital heart anomaly (cor triatriatum sinister, CTS) in families from the
Amish community and Northern Saudi Arabia of Arabic ethnicity. Mice who lack this
enzyme show similar features. HYAL2 is involved in the metabolism of hyaluronic acid,
which is important in many tissues of the body. By illustrating a lack of HYAL2 causes
CLP and CTS we have demonstrated the importance of HYAL2 for the normal develop-
ment of the palate and heart, improving our understanding of the complex mechanisms
involved in the pathogenesis of CLP and CTS which may ultimately contribute to the
development of novel therapies to treat these congenital anomalies.
Introduction
Orofacial clefts, which include cleft lip (CL) with or without cleft palate (CLP) and cleft palate
alone (CP), collectively referred to as CL/P, are amongst the most common birth defects in all
populations worldwide with many syndromic and non-syndromic forms described. The
majority of cases are of unknown molecular cause [1]. The average incidence of CL/P is one in
700 newborns, with wide variability across racial and ethnic groups and socioeconomic status
[2, 3]. The frequency of CL/P also differs by gender and laterality, there being a 2:1 male to
female ratio for CLP, and a 1:2 male to female ratio for CP [2, 4]. Orofacial clefts arise from a
failure of the intricate molecular and cellular processes that regulate bilateral fusion of the
future lip and palate during craniofacial development [1]. They are clinically categorized
dependent upon the absence (non-syndromic CL/P; 70% of cases) or presence (syndromic
CL/P; 30% of cases) of additional congenital anomalies [5, 6]. For non-syndromic CL/P, 17
genetic risk loci have been defined and replicated with genome wide association studies world-
wide [7–11]. As well as environmental influences, more recent evidence implicates non-coding
or regulatory genomic regions in non-syndromic CL/P [12–14], perhaps explaining why re-
sequencing of candidate genes or exome sequencing strategies rarely identify mutations in
these cases [15]. For syndromic forms of CL/P, >300 different syndromes have been described
in which CL/P is a prominent feature [16]. Congenital heart disease (CHD) is commonly asso-
ciated with syndromic CL/P with a reported incidence of 13%-27% [15, 17–22]. Cor triatria-
tum is a rare congenital cardiac anomaly reported in 0.1–0.4% of individuals with congenital
heart disease [23, 24]. It is characterized by division of either the left (cor triatriatum sinister)
or less commonly the right atrium (cor triatriatum dexter) [25, 26]. To date, no molecular
cause has been identified for cor triatriatum in humans. In the current study, we identify
mutations in the gene HYAL2 as a new genetic cause of orofacial clefting in humans and mice
and describe the first molecular basis for cor triatriatum sinister in humans. Our findings
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illustrate the fundamental importance of hyaluronan (HA) turnover for normal human and
mouse development.
Results
Clinical findings
Amish pedigree. Five Amish individuals aged 4–16 years affected by a novel syndromic
form of CLP were identified from a single extended pedigree consisting of three interlinking
kindreds within the Amish community (Fig 1A). Bilateral or unilateral CLP and consistent cra-
niofacial dysmorphism are the principal features of the condition. Additional clinical findings
include congenital cardiac anomalies, pectus excavatum, single palmar creases, hearing loss that
was predominantly conductive in nature, myopia and other ocular abnormalities including cat-
aract and staphyloma. 2–3 soft tissue syndactyly of the toes was found on examination of the
Amish affected individuals, but was also seen in unaffected members of the family. Craniofacial
features included frontal bossing, hypertelorism, widened and flattened nasal bridge and tip,
cupped ears/thickened helices and micrognathia. Cardiac anomalies observed were variable but
interestingly included non-obstructive cor triatriatum sinister (dividing the pulmonary venous
confluence from the body of the left atrium with an anterior fenestration in the membrane).
Saudi Arabian pedigree. Two children aged 7 and 12 years from an extended consan-
guineous Arab family from Northern Saudi Arabia were previously identified [27]. On com-
parison with the Amish family, significant similarity in the clinical features was noted. Most
notably, the presence of bilateral cleft lip and palate in one affected girl and a similar facial
appearance with frontal bossing, hypertelorism, micrognathia, and a broad flat nasal bridge.
Both girls also had bilateral single palmer creases, lens opacities, staphyloma and were myopic.
Echocardiography had only been carried out on the youngest affected girl and revealed an
abnormal mitral valve with accessory tissue and a small restrictive perimembranous ventricu-
lar septal defect covered with tricuspid aneurysmal tissue. The older affected girl had pectus
excavatum but cardiovascular examination was otherwise normal.
The clinical features of the affected individuals are summarized in Table 1 and shown in Fig
1A. Whereas it is normal for mice to have a left sided superior vena cava, there is regression of
the left superior cardinal vein caudal to the innominate vein during normal human develop-
ment and only the failure of this regression leads to the persistence of a left sided superior vena
cava (PLSVC). A PLSVC represents the most common congenital thoracic venous anomaly
with a prevalence of 0.3–0.5% in the general population [28]. In 80–90% of individuals, the
PLSVC drains into the right atrium via the coronary sinus, which leads to a dilated coronary
sinus, but usually has no hemodynamic consequence [29].
Genetic studies
In order to map the chromosomal location of the disease gene we undertook a genome-wide
SNP study in affected members of Family 1 assuming that a recessive founder mutation was
responsible. This identified a single notable shared autozygous region of 10.18Mb on chromo-
some 3p21.31 (rs6441961-rs2201057; chr3:46310893–56499374 [hg38]) as likely to correspond
to the disease locus. In support of this, multipoint linkage analysis with Simwalk2 [30] assum-
ing autosomal recessive inheritance, full penetrance and a disease allele frequency of 0.0001,
achieved a LODMAX = 10.37 corresponding to the autozygous interval. To identify the causa-
tive mutation, whole exome sequence analysis of a single affected individual (XII:3) was un-
dertaken (Otogenetics Corporation). After filtering for call quality, potential pathogenicity,
population frequency and localization within the candidate interval, we identified only a single
likely deleterious variant located in the HYAL2 gene (HYAL2 chr3:g.50320047T>C [hg38];
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Fig 1. Pedigrees, clinical features of individuals homozygous for HYAL2 mutation and identified HYAL2
mutations, expression of wild type (WT), K148R-HYAL2 and P250L-HYAL2. (A) Pedigree diagrams and
facial phenotype of individuals (Amish Family 1: XII:7; XII:9; XII:12 and Saudi Family 2: VI:2) with HYAL2
deficiency. Note the craniofacial similarities including frontal bossing, hypertelorism, widened nasal bridge,
flattened broad nasal tip and cupped ears/overfolding of the superior helices. Consent for publication of these
photographs was obtained (B) Electropherograms showing the identified c.443A>G & c.749C>T mutations and
conservation of protein sequence across species.(C) Expression of wild type (WT), K148R and P250L-HYAL2.
Western blots were performed on lysates prepared from MEFs deficient in HYAL2 that were transfected with
HYAL2 Orofacial Clefting and Cor Triatriatum Sinister
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NM_003773.4:c.443A>G; p.K148R; PolyPhen = probably damaging (1); SIFT = deleterious
(0.03) MutationTaster = disease causing (probability 0.999997) Fig 1B). The variant was vali-
dated by Sanger dideoxy sequencing, which was also used to confirm co-segregation of the
variant within the extended Amish pedigree (Fig 1A). Seven heterozygous carriers of the
c.443A>G variant were identified in 532 Amish control chromosomes examined, indicating
an allele frequency of approximately 0.013 in the population. The variant was not listed in the
Exome Variant Server (NHLBI GO Exome Sequencing Project (ESP), Seattle, WA; http://evs.
gs.washington.edu/EVS/), 1000 Genomes browser (http://browser.1000genomes.org/index.
html) or the Exome Aggregation Consortium (ExAC) database (http://exacbroadinstitute.org/
). Interestingly, HYAL2 had recently been identified as a candidate gene as a cause of short stat-
ure and facial dysmorphism in a study of multiplex consanguineous families [27]. This study
undertook genetic studies in 33 heterogeneous families with dysmorphic and other systemic
clinical manifestations, and identified a sequence alteration in HYAL2 as a possible cause of
the clinical features in a single family comprising two affected individuals (Fig 1A, Family 2).
Although inconclusive, when considered together with the genetic, clinical and functional data
from the Amish study, this permits the robust genetic definition and clinical description of a
new form of syndromic CLP. Genetic studies in Family 2 comprised whole genome SNP
mapping which identified a single autozygous interval of 13.49Mb on chromosome 3p21
(rs7650433-rs9811393; chr3:40857673–54345775 [hg38]) shared by two affected family mem-
bers, in which a missense HYAL2 variant (chr3:g.50319741G>A [hg38]; NM_003773.4:
c.749C>T; p.P250L in Family 2; Fig 1A and 1B), absent in 817 ethnically matched individuals,
was identified as the candidate genetic cause. This variant (rs781999115) was not listed in the
Exome Variant Server or the 1000 Genomes browser but two carriers were reported on the
ExAC database. The genomic autozygous region (chr3:46310893–54379802 [hg38]) common
to both family cohorts is 8.0Mb and predicted to contain 270 RefSeq alignment-supported
transcripts (S1 Fig).The p.K148R and p.P250L substitutions decrease protein stability.
HYAL2 encodes hyaluronidase 2, a membrane localized protein [33] with weak activity
toward HA [34], which is an extracellular matrix glycosaminoglycan that is abundant during
development. To assess the impact of p.K148R and p.P250L on the HYAL2 protein, the muta-
tions were each introduced into a human HYAL2 expression construct and transiently trans-
fected into MEFs deficient in HYAL2. Western blot analysis revealed a profound effect of the
p.K148R and p.P250L mutations on protein levels, resulting in 11 and 20 fold reductions,
respectively, compared to wild type (Fig 1C).
Evaluation of craniofacial features and palate in Hyal2-/- mice
Consistent with the facial dysmorphism in the human affected individuals, Hyal2-/- mice
exhibited a short broad nose, increased interorbitary space, and Wormian bones in the inter-
frontal suture [35]. To determine if the CL/P seen in the human affected individuals was also
present in Hyal2-/- mice, we examined the time of pre-weaning lethality described to affect 2/3
of knockouts [35, 36]. Among 201 progeny of Hyal2+/- intercrosses followed from birth to
weaning, 16 died at postnatal day (P)1, 16 died between P2-P9, and 16 Hyal2-/- mice survived
(S1 Table). Assuming all pups that died were Hyal2-/-, 48 of 201 progeny (24%) would be
Hyal2-/-, approximating the Mendelian frequency for an autosomal recessive condition. We
empty vector, pCMV6-HYAL2, pCMV6-HYAL2K148R, or pCMV6-HYAL2P250L. An arrow indicates HYAL2.
HYAL2 levels shown in the graph were quantified by imaging the chemiluminescent signal using a BioRad
ChemiDoc. The columns represent the average level (x 106 light units) of HYAL2 ± SEM (n = 4). Significance was
determined using the student’s T test. *** indicates p<0.0001.
doi:10.1371/journal.pgen.1006470.g001
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Table 1. Clinical findings of individuals homozygous for HYAL2 mutations
FAMILY 1 FAMILY 2
XII:3 XII:5 XII:7 XII:9 XII:12 V:3 VI:2
GENDER Male Male Female Female Male Female Female
HYAL2 MUTATION c.443A>G c.443A>G c.443A>G c.443A>G c.443A>G c.749C>T c.749C>T
AGE (YRS) 12.3 15.5 4.3 9.9 12.7 7.1 12.3
GROWTH
Height (SDS) -0.54 0.45 -1.07 0.29 -0.4 -2.87 -2.87
Head
circumference
(SDS)
-0.67 -0.22 -0.28 -0.49 -1.6 -3.13 -2.59
SKELETON
Pectus excavatum - ✓ ✓ - ✓ - ✓
CRANIOFACIAL
FEATURES
Cleft lip and palate Bilateral CLP RT unilateral
CLP
Bilateral CLP Bilateral CLP Bilateral CLP None Bilateral CLP
Frontal bossing Not known Not known ✓ - ✓ - -
Hypertelorism ✓ ✓ ✓ ✓ ✓
Micrognathia ✓ ✓ ✓ ✓ ✓
Broad flat nasal
bridge
✓ ✓ ✓ ✓ ✓
Ears - Over folded
superior
helices
- Cupped ears Cupped ears
HEART
Congenital cardiac
malformations
LT cor
triatriatum
Dilated
coronary
sinus
consistent
with
persistent
LSVC
Normal
echocardiogram
Dilated
coronary
sinus
consistent
with
persistent
LSVC
Normal
echocardiogram
Abnormal MV with
accessory tissue
Normal
echocardiogram
Small restrictive
perimembranous
VSD covered with
tricuspid aneurysmal
tissue
Other cardiac
abnormalities
Thickened AV Dilated LT
and RT atria
Mild TR
Restricted RT
aortic leaflet
Lt-Rt shunt
Mild AR Mildly dilated LV
EYES
Visual acuity Glasses since
age 2
Glasses since
age 6
Normal Glasses since
age 9
Glasses since
age 9
Glasses since age 3 Glasses since
age 4
RT myopia
-8.00
RT myopia
-1.50
RT myopia -2.50 RT myopia -16.75 RT myopia -9.75
LT hyperopia
+3.25
LT hyperopia
+1.75
LT myopia -2.50 LT myopia -15.00 LT myopia
-16.00
Other ocular
abnormalities
Rt staphyloma Cortical lens opacities
and staphyloma with
small disc
Corneal opacity
Myopic macular
degeneration
- - - - High myopia
(Continued )
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also studied ninety E18.5 embryos from Hyal2+/- intercrosses and found two Hyal2-/- and one
Hyal2+/- embryo(s) that had died at approximately E15.5. Taking these intrauterine deaths
into account, the proportion of Hyal2+/+ mice still exceeded that of Hyal2-/- mice (30% vs 24%,
S1 Table). Although this difference did not reach significance, it suggested reduced survival of
Hyal2-/- and Hyal2+/- embryos during early gestation.
CL/P was a likely cause of death in Hyal2-/- mice at P1 and possibly between P2-P9, whereas
heart defects were the more probable cause at E15.5. Although most deceased pups were canni-
balized before their genotype could be verified, four found dead at P1, without milk in their
stomachs, were identified as Hyal2-/-. Micro-CT studies of these pups showed an underdevel-
oped and underossified viscerocranium compared to littermate controls (Fig 2Ai-ii). Several
central palate bones were underdeveloped and the vomer did not fuse centrally or form a head
that articulated with the maxilla (Fig 2Aiii-vi). The ethmoid bone was nearly absent (Fig 2Ai-
ii), or severely reduced in size (S2C and S2D Fig). This underdevelopment of the viscerocra-
nium indicated a defect in intramembranous ossification that was more prominent in the ante-
rior midline and varied in severity among affected skulls (S2A–S2D Fig).
Table 1. (Continued)
FAMILY 1 FAMILY 2
XII:3 XII:5 XII:7 XII:9 XII:12 V:3 VI:2
Posterior
subcapsular
polar cataract/
Mittendorf dot
Flat retina
Staphyloma and
LT retinal scar
HEARING
Conductive
hearing loss
RT moderate - Bilateral mild - LT moderate RT Mild -
Postlingual Prelingual
Sensorineural
hearing loss
- Bilateral
severe to
profound
- - - - -
Prelingual
LT cochlear
implant
NORMAL
PSYCHOMOTOR
DEVELOPMENT
✓ ✓ ✓ ✓ ✓ ✓ ✓
HANDS AND FEET Not known Not known Single palmar
crease - LT hand
Bilateral single
palmar creases
Bilateral single palmar
creases
Bilateral single
palmar creases
Bilateral 2-3 and
3-4 skin
syndactyly of toes
Bilateral 2-3
and 3-4 skin
syndactyly of
toes
Bilateral 2-3 skin
syndactyly of
toes
Broad thumbs
Acromelia
Abbreviations; SDS, standard deviation scores; (✓), indicates presence of a feature in an affected subject; (-), indicates presence of a feature in an affected
subject); CLP, Cleft lip and palate; RT, Right; LT, Left; AV, Aortic valve; AR, Aortic regurgitation; LSVC, Left superior vena cava; LV, Left ventricle; VSD,
Ventricular septal defect; TR, Tricuspid regurgitation; LV, Left ventricle
Height, weight and OFC Z-scores were calculated using a Microsoft Excel add-in to access growth references based on the LMS method [31] using a
reference European population [32]
doi:10.1371/journal.pgen.1006470.t001
HYAL2 Orofacial Clefting and Cor Triatriatum Sinister
PLOS Genetics | DOI:10.1371/journal.pgen.1006470 January 12, 2017 7 / 17
Fig 2. Micro-CT images of the skulls of Hyal2-/- and Hyal2+/- mice, transthoracic echocardiography images
of Amish individuals homozygous for HYAL2 mutation c.443A>G, cardiac analysis in Hyal2-/- and Hyal2+/+
mice (A) 3D Images of Hyal2-/- mice that died at P1, and the control (Hyal2+/-) which was sacrificed at P2, were
created using CTvox software. All images were scanned and reconstructed using identical parameters and the
dynamic range for the grey scale was held constant (i and ii). Dorsal views from the rostral end of the skull were
prepared using a transfer function that colorized the grey scale such that areas of the bone with lower density are
red (see density scale in image). (iii and iv). Ventral grey scale views of the skulls without the lower jaw. (v and vi).
Space filled images of the vomer. * indicates the vomer head. Similar findings were evident in three additional
Hyal2-/- mice found dead at P1. These images are not to scale. E, ethmoid; V, vomer; PS, presphenoid; BS,
basisphenoid; PM, premaxilla; MA, maxilla; PA, palantine. (B) (i & ii) Apical 4-chamber image of the heart is shown
HYAL2 Orofacial Clefting and Cor Triatriatum Sinister
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Characterization of the palates of Hyal2-/- E18.5–19.5 embryos under a dissecting micro-
scope revealed partial clefts and/or shortening of the secondary palate as well as abnormally
formed rugae in most Hyal2-/- mice and a small number of Hyal2+/- mice (S3A–S3D Fig).
Micro-CT confirmed reduced ossification and underdevelopment of the viscerocranial bones,
particularly the vomer, consistent with submucosal cleft palate (SMCP) in 15 of 18 (83%; 95%
CI 58–96%) Hyal2-/-, 3 of 54 (5.6%; 95% CI 1–16%) Hyal2+/-, and 0 of 23 (0%; 95% CI 0–18%)
Hyal2+/+mice. Palatal malformation and clefting are likely to contribute significantly to the
pre-weaning lethality in Hyal2-/- mice, indicating further phenotypical overlap with the human
condition.
Histological studies of P1 mice confirmed that the viscerocranial bones of all Hyal2-/- mice
were underdeveloped (S3E and S3F Fig, and arrows in N, O). Coronal sections showed the
failed fusion between the epithelial surface of the vomeronasal organ and the dorsal side of the
palate shelf ( in S3L and S3N Fig), leaving an average gap of 472 ± 50μm (n = 3) in Hyal2-/-
palates that was absent in control palates (S3M and S3O Fig). HA levels were clearly increased
in the Hyal2-/- tissues (S3J and S3N vs S3K and S3O Fig). Excess mesenchymal cells and their
surrounding matrix, was also evident, particularly in the anterior head ( in S3H and S3I Fig).
Evaluation of the heart in Hyal2-/- mice
Valvular thickening and atrial dilatation are found in all Hyal2-/- mice, although the severity of
the phenotype varies [36]. Cor triatriatum sinister has been detected in 50% of Hyal2-/- mice
([37] and Fig 2B). It is conceivable that deaths in the progeny of Hyal2+/- intercrosses during
embryogenesis and between P2-P9 observed are due to more severe (congenital) cardiac
anomalies in Hyal2-/- mice. The cardiac findings in the five individuals with the HYAL2
K148R variant display significant similarities including one individual with cor triatriatum sin-
ister and two further individuals with dilated coronary sinuses indicative of a PLSVC (see
Table 1 and Fig 2C). This provides convincing evidence of the importance of HYAL2 for nor-
mal heart development in humans and mice [36, 37] and identified mutation of HYAL2 as the
first described molecular mechanism for cor triatriatum sinister in humans.
Evaluation of hearing in the Hyal2-/- mice
Although conductive hearing loss was seen in most of the affected human subjects in this
study, one affected individual was found to have profound sensorineural hearing loss. To
assess hearing in Hyal2-/- mice (8–12 weeks of age), the auditory brainstem response (ABR)
was evaluated (S4 Fig). Hyal2-/- mice exhibited a significantly higher threshold at all frequen-
cies tested, (mean +/- 95% confidence interval for Hyal2-/- and Hyal2+/+ mice were 17.6
+/-7.16 and 5.00 +/-3.88dB respectively; Mann-Whitney U-test U = 1433, p<0.001), indicating
hearing loss in 100% of Hyal2-/- mice. The ABR test parameters did not differentiate conduc-
tive and sensorineural hearing loss, but because these were performed on adult mice, severe
craniofacial defects were excluded, although minor defects may be present. The presence of
hearing loss in mice without severe palate defects suggests more studies are needed to
with right atrium (RA), left atrium (LA), right ventricle (RV), and left ventricle (LV) labelled. Presence of membranous
tissue (*) in the LA of Hyal2-/- mouse representing cor triatriatum sinister. (C) (i) Apical four chamber view of Amish
individual XII:3: arrow indicates the membrane across the left atrium dividing the pulmonary venous confluence
from the body of the left atrium (cor triatriatum sinister). (ii) Apical three chamber view with color. Doppler of
individual XII:3: arrow indicates the anterior fenestration in the membrane dividing the left atrium, the laminar flow
through the fenestration implies the non-obstructive nature of the membrane. (iii) Apical two chamber view of
individual XII:9: arrow indicates the dilated coronary sinus indicative of a persistent left superior vena cava; RV: right
ventricle, RA: right atrium, LV: left ventricle, LA: left atrium, CS: coronary sinus.
doi:10.1371/journal.pgen.1006470.g002
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determine whether HYAL2 has a direct role in the development and/or maintenance of nor-
mal hearing.
HA accumulation in Hyal2-/- deficiency
Previous studies of Hyal2-/- mice with a complete absence of HYAL2 activity have demon-
strated levels of circulating HA that are 19 fold higher than that of control mice at 12 weeks of
age and accumulation of HA in the heart and lung [36] as well as other tissues [37]. In the cur-
rent study, the HA levels were clearly elevated throughout the nasopharynx and in the palate
(S3J, S3K, S3N and S3O Fig). It remains unclear to which degree this reflects species differ-
ences, but this finding is consistent with our transfection studies which show residual HYAL2
is present. This level of HYAL2 may be sufficient for constitutive turnover, but inadequate
during development when rapid turnover of high levels of HA in the provisional matrix is
required.
Discussion
The molecular basis of human CLP is incompletely understood, despite its frequent occur-
rence and associated morbidity. Our findings demonstrate that a deficiency of the HA-degrad-
ing enzyme HYAL2 is a novel cause of syndromic CLP in humans and SMCP in mice, and
define the first molecular explanation for cor triatriatum sinister in humans. All but one
affected individual exhibited orofacial clefting, and craniofacial dysmorphism was a consistent
finding. Myopia and other ocular abnormalities, pectus excavatum, single palmar creases, cor
triatriatum sinister, a persistent left superior vena cava and other cardiac features were variably
present. Our studies show that Hyal2-/- mice universally exhibit facial dysmorphism, an under-
development of the viscerocranium and cardiac valve thickening as well as variably penetrant
hearing loss, partial or SMCP (83%), cor triatriatum sinister (50%) and atrial dilatation (50%).
The significant parity between the human and mouse phenotypes provides strong evidence
that HYAL2-deficiency is the cause of these developmental abnormalities.
Our data indicate that the differences between the human and mouse phenotypes may be
largely explained by the complete absence of HYAL2 in Hyal2-/- mice, while the destabilizing
and deactivating p.K148R and p.P250L HYAL2 substitutions identified in human affected indi-
viduals lead primarily to profound reductions in HYAL2 levels, which may still permit limited
residual functionality. In surviving Hyal2-/- mice progressive accumulation of HA in the circula-
tion, pulmonary fibrosis, and cardiac dysfunction lead to premature heart failure [36], while the
absence of elevated circulating HA in the affected Amish individuals may partially or completely
protect them from these cardiopulmonary complications. The residual activity associated with
the amino acid substitutions in human subjects likely supports ongoing constitutive turnover of
HA, but is insufficient for the rapid and regulated turnover required during development. Fur-
ther support for this is provided by our study of Hyal2+/- mice where a small number showed
developmental abnormalities in the absence of elevated circulating HA [36]. However, this may
be an overly simplistic interpretation as circulating HA levels are approximately 10–20 fold
higher in the mouse, despite similar rates of turnover in mice and humans [38]. The identifica-
tion of additional HYAL2-deficient individuals would undoubtedly provide a more complete
understanding of the phenotypic spectrum associated with HYAL2-deficiency.
We identified SMCP as a likely cause of early pre-weaning lethality in Hyal2-/- mice.
The underdeveloped viscerocranium likely weakens the palate, and in combination with the
facial dysmorphism, presents significant feeding difficulties for Hyal2-/- suckling pups. Neuro-
logical abnormalities could also contribute to death, as the cribriform plate of the ethmoid is
important in supporting the olfactory bulb and in preventing the leakage of cerebrospinal fluid
HYAL2 Orofacial Clefting and Cor Triatriatum Sinister
PLOS Genetics | DOI:10.1371/journal.pgen.1006470 January 12, 2017 10 / 17
into the nasal cavity. The bones of the viscerocranium have not yet been examined in affected
individuals with the HYAL2 variant, but defects of the vomer are common in affected individu-
als with CLP [39]. The identification of developmental abnormalities in a small number of het-
erozygous (Hyal2+/-) mice suggests that haploinsufficiency of HYAL2 may also pose the risk of a
similar outcome in humans. Consistent with the notion that altered HYAL2 levels may affect
palatal development, decreased HA has previously been associated with increased risk for CP in
the Tbx1-/- mouse [40], whereas increased HA has been associated with CP in Sim2-/- mice [41].
Thus, HYAL2 variants may be considered as candidates, even in the heterozygous form, to con-
fer risk for these developmental abnormalities. However screening a cohort of non-syndromic
CL/P individuals, provided little evidence for a major role for HYAL2 in this cohort (personal
communication- P. Stanier). The cohort consisted of 380 individuals (176 with unilateral or
bilateral cleft lip and palate, 38 with cleft lip only, 121 with cleft palate only and 46 with submu-
cous cleft palate) of a mixture of ethnicities the majority of which (72%) were of white European
origin recruited from the North East Thames region of the UK. Approximately 22% of cases
were familial with affected first or second-degree relatives. While this study cohort is too small
to draw definitive genotype-phenotype conclusions, this finding remains consistent with
HYAL2 mutation being likely only associated with a rare, autosomal recessive syndrome.
Eloquent studies in mice deficient in HA synthesis (Has2-/-) demonstrated that high molec-
ular mass HA was essential for epithelial to mesenchymal transition (EMT) in the developing
heart, whereas HA oligosaccharides inhibited EMT and promoted angiogenesis [42–44].
HYAL2 could modulate the size of HA to inhibit EMT and promote differentiation, in which
case its deficiency would result in increased levels of high molecular mass HA, an overproduc-
tion of mesenchymal cells, and a decrease in differentiation. Indeed, the thickened cardiac
valves and excess mesenchymal cells in some parts of the head of Hyal2-/- mice, suggest that
EMT is upregulated in Hyal2-/- mice, and that HYAL2 normally plays a role in inhibiting this
process. In histological sections, encompassing the nasopharynx and secondary palate, there is
an abundance of cartilage but a deficiency in bone. The deficient ossification in the skull of
Hyal2-/- mice, and underdevelopment of the viscerocranium, suggests a failure in the develop-
ment of osteoblasts, as has been seen in Tbx22-/- mice [45].
In addition to the direct effects of HA on signaling pathways, it is possible that an overabun-
dance of HA in Hyal2-/- tissues leads to alterations in the gradients of morphogens or signal
transduction factors, impacting development. Clearly further studies are needed to investigate
this possibility. Treatment strategies for this developmental disorder deserve further research,
as HA synthesis can be inhibited using 4-methylumelliferone, an FDA-approved drug in some
parts of the world [46]. Further, commercial preparations of human hyaluronidase that func-
tion at a neutral pH could be used to remove extracellular HA; these enzymes are available for
human use [47], and formulations that are stable in the circulation are under development
[48]. With the Hyal2-/- mouse model already available, testing of such strategies may enable the
development of a pre-natal treatment for this malformation syndrome. Taken together, our
findings highlight hyaluronidase enzymes as playing a vital role in both human and mouse
development, and in particular have revealed a previously unrecognized pathway involved in
the pathogenesis of orofacial clefting, myopia and cor triatriatum sinister in humans, which
may ultimately be amenable to treatment therapies.
Materials and Methods
Ethics statement
Signed consent was obtained for all individuals and the study was approved by the institutional
review board at the University of Arizona (reference 10-0050-01) and the Great Ormond Street
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Hospital and the Institute of Child Health Research Ethics Committee (REC No. 08H0713/46).
Animals were euthanized by isoflurane overdose and embryos were collected for gross mor-
phological or histological studies. All procedures were in compliance with the Canadian Coun-
cil on Animal Care and followed a protocol approved by the University of Manitoba Animal
Care Committee.
Genetic studies
Blood samples for DNA extraction were obtained with informed consent from all participating
family members (institutional review board-approved research protocols UoA:10-0050-10 and
KFSHRC RAC#2080006). A genome-wide SNP screen was undertaken in the affected siblings
(Family 1: XII:3; XIII:5; XII:7; XII:9; XII:12, and Family 2: V:3; VI:2) using Illumina Human-
CytoSNP-12 v2.1 or Axiom SNP Chip arrays for autozygosity mapping of regions of>1Mb
using AutoSNPa [49]. Whole exome sequencing of genomic DNA from Family 1 was per-
formed at Otogenetics Corporation (Norcross, GA, USA) using the Agilent SureSelect Human
All ExonV4 (51Mb) enrichment kit with a paired-end (2 × 100) protocol at a mean coverage of
30X. For Family 2, we used a TruSeq Exome Enrichment kit (Illumina, San Diego, CA) with
samples prepared as an Illumina sequencing library enriched for the desired targets using the
Illumina Exome Enrichment, with captured libraries sequenced using an Illumina HiSeq 2000
Sequencer. Sequence reads were aligned to the human genome reference sequence [hg19] and
read alignment, variant calling, and annotation were performed by DNAnexus (DNAnexus
Inc, Mountain View, CA). Intronic variants not predicted to affect splicing or regulation were
excluded and SIFT [50], PolyPhen-2 [51], and MutationTaster [52] was used to predict the
impact of any identified amino acid substitution on the protein structure and function and to
predict and prioritize potential disease causing sequence alterations. The presence of the vari-
ants were confirmed in the transcript by bidirectional dideoxy Sanger sequencing performed
on an ABI3730 XL capillary sequencer (Applied Biosystems), which was also used to confirm
its co-segregation within the respective pedigrees.
Experimental animals
Hyal2-/- (null) mice and littermate controls (Hyal2+/- or Hyal2+/+) were obtained from hetero-
zygous intercrosses of mice maintained on an outbred (C129; CD1; C57BL/6) background as
viable Hyal2-/- mice have not been obtained on an inbred background [35]. Embryos were con-
sidered E0.5 the morning a vaginal plug was discovered. Genotyping was performed as
described [36]. Animals were euthanized by isoflurane overdose and embryos were collected
for gross morphological or histological studies. All procedures were in compliance with the
Canadian Council on Animal Care and followed a protocol approved by the University of
Manitoba Animal Care Committee.
Animal imaging, hearing analysis and histological studies
Ultrasound imaging was performed on mice anesthetized with 2% isoflurane, using a Visual
Sonics Vevo 2100 ultrasound equipped with a 40 MHz transducer. Micro-CT imaging was per-
formed at 9μm resolution with a Skyscan 1176 micro-CT and images were reconstructed and
analyzed using Bruker’s NRecon, Data Viewer, CT Analyzer, or CT Vox software. ABR testing
was performed as described previously [53]. Skeletal staining of neonatal mice was as described
in [54]. For histological studies, tissues were fixed in 1% cetylpyridinium chloride in 10% buff-
ered formalin, decalcified if appropriate, imbedded in paraffin, and 5μm sections were pre-
pared. Sections were stained with H & E for analysis of morphology. HA was detected using
the HA binding protein (HABP) following established protocols [36].
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HA and hyaluronidase assays
HA levels were determined using a DuoSet enzyme linked immunosorbent assay (ELISA)
development kit (R & D Systems).
Transient transfection and western blot analysis
Transfections of HYAL2-expressing vectors were into mouse embryonic fibroblasts (MEFs)
derived from a Hyal2-/- embryo. Cells and culture medium were collected 48 hours post-trans-
fection and the β-galactosidase activity was determined using O-nitrophenol-β-D-galactopyra-
noside as a substrate [55]. Protein concentrations in the lysates were determined using a
BioRad protein assay kit based on the Bradford method, and β-galactosidase levels were used
to normalize for transfection efficiency in all assays. Western blot analysis was as described
previously, but using polyclonal anti-HYAL2 (Proteintech) [56].
Supporting Information
S1 Table. Genotypes and survival of progeny of Hyal2+/- intercrosses.
(DOCX)
S1 Fig. Visualization of regions of genetic homozygosity. Pictorial representation of the SNP
genotype data encompassing the chromosome 3 homozygous regions in affected individuals.
The locus containing the pathogenic variant is demarcated by SNPs (rs6441961 and rs9811393
8.03Mb; 270 genes).
(TIF)
S2 Fig. Visualization of the skulls of Hyal2-/- and Hyal2+/- mice. The skulls of Hyal2-/- mice
that died at P1, and of a Hyal2+/- mouse that was sacrificed at P2, were visualized by skeletal
staining (A,B) or micro-CT imaging (C,D). (A and B) Photographs of the anterior region of
the viscerocranium after removal of the skull. The ethmoid (E) bone is severely underdevel-
oped in the Hyal2-/- mouse compared to the Hyal2+/- mouse. For micro-CT imaging, the scan-
ning and reconstruction parameters, including the dynamic range of the grey scale, were the
same for all images. (C and D) 3D micro-CT grey scale images of the ethmoid bone that is
almost absent in the Hyal2-/- mouse, but well developed in the Hyal2+/- control. E-ethmoid
bone.
(TIF)
S3 Fig. Analysis of the palates of Hyal2-/-, Hyal2+/-, and Hyal2+/+ mice. (A-D) Photographs
were taken of the ventral surface of the head of E18.5 embryos after removing the bottom man-
dible. Arrows indicate partial cleft palates indicative of submucosal cleft palate. (E—G) Histo-
logical analysis of Hyal2-/- and Hyal2+/+ P1 heads. Sagittal sections were stained with H & E.
The reduction in staining intensity indicates reduced ossification in Hyal2-/- mice compared to
controls. The schematic in (G) indicates the identity of the bones: PM, premaxilla; MA, maxilla;
PA, palantine; PS, presphenoid; BS, basisphenoid (H-I). Coronal sections through the nasophar-
ynx and secondary palate of E18.5 embryos were stained for morphological analysis with hema-
toxylin and eosin. Areas with excess mesenchymal cells in the Hyal2-/- mouse are indicated with
asterisks. (J and K) Hyaluronan (brown) detected in coronal sections of the nasopharynx. (L
and M) H & E staining of the fusion between the vomeronasal organ and palate. An  indicates
the failed fusion in the Hyal2-/- mouse. (N and O) Hyaluronan (brown) detection in the region
of the vomeronasal/palate fusion. An  indicates the failed fusion between the vomeronasal
organ and primary palate. A black arrow indicates the underdeveloped vomer and a green
arrow indicates the underdeveloped maxilla. All images are representative of a minimum of 3
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sets of Hyal2-/- and control mice.
(TIF)
S4 Fig. Hearing analysis in Hyal2-/- and Hyal2+/+ mice. Evaluation of hearing in Hyal2-/- and
control (Hyal2+/+) mice was assessed by the ABR (auditory brain stem response) at varying fre-
quencies and intensities These values are based on the average of 16 ears (8 mice) for each
genotype The bars represent the mean threshold and the 95% confidence interval.
(TIF)
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